BioNTech SE (BNTX)

Vienna
Currency in EUR
91.40
-0.95(-1.03%)
Closed·

NASDAQ:BNTX Financials

Key Ratios

P/E Ratio-27.98
Price/Book1.13
Debt / Equity1.55%
Return on Equity-3.94%
Dividend Yield0.00%
EBITDA-1.03B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa17,310.63,8192,751.1
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa14,315.63,219.22,209.8
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa11,918.3971.8-1,285.5
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa9,434.4930.3-665.3
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa23,279.123,006.322,529.7
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa2,950.62,070.52,523.2
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa20,055.620,245.919,411.1
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa12,008.534,138.74534.99
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa13,577.45,371.4207.7
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-35.3-6,954.5-2,081.2
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-1,419.3-778.6-45.9
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa12,182.4-2,211.4-1,901.8
* In Millions of EUR (except for per share items)

Earnings

Latest Release
May 05, 2025
EPS / Forecast
-1.73 / -2.00
Revenue / Forecast
182.80M / 204.08M
EPS Revisions
Last 90 days

FAQ

What were BioNTech SE's earnings for the latest quarter?

The BioNTech SE EPS (TTM) is -3.19. BioNTech SE reported sales of 182.80, net income of -415.80, and EPS of -1.73 for the latest quarter.

What was BioNTech SE's net income for the latest quarter?

BioNTech SE's net income for the latest quarter was -415.80.

How did BioNTech SE's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,190.00 in the previous quarter to 182.80 in the latest quarter, and net income moved from 259.50 to -415.80 compared to the previous quarter.

What is BioNTech SE's net profit margin on a TTM basis?

BioNTech SE's trailing twelve months (TTM) net profit margin is -24.18%.

How does BioNTech SE's debt to equity ratio compare to industry standards?

BioNTech SE's total debt-to-equity ratio is 1.55%.

What is BioNTech SE's return on investment on a TTM basis?

BioNTech SE's trailing twelve months (TTM) return on investment (ROI) is -3.94%.

Did BioNTech SE gain or lose cash last quarter?

In the latest quarter, BioNTech SE's net change in cash was 423.00 million.

What were BioNTech SE's total assets and liabilities in the latest quarter?

As of the latest quarter, BioNTech SE reported total assets of 21,182.40 million and total liabilities of 1,534.50 million.

How has BioNTech SE's total revenue grown this year?

BioNTech SE's total revenue was 1,190.00 in the previous quarter and 182.80 in the latest quarter.

What is BioNTech SE's gross margin on a TTM basis?

BioNTech SE's trailing twelve months (TTM) gross margin is 79.39%.

What was BioNTech SE's revenue per share for the latest quarter?

BioNTech SE's revenue per share for the latest quarter was 88.03.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.